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dc25 phosphatases are essential for the activation
of mitotic cyclin–Cdks, but the precise roles of the
three mammalian isoforms (A, B, and C) are un-
clear. Using RNA interference to reduce the expression of
each Cdc25 isoform in HeLa and HEK293 cells, we ob-
served that Cdc25A and -B are both needed for mitotic
entry, whereas Cdc25C alone cannot induce mitosis. We
found that the G2 delay caused by small interfering RNA
to Cdc25A or -B was accompanied by reduced activities
C
 
of both cyclin B1–Cdk1 and cyclin A–Cdk2 complexes
and a delayed accumulation of cyclin B1 protein. Further,
three-dimensional time-lapse microscopy and quantiﬁca-
tion of Cdk1 phosphorylation versus cyclin B1 levels in in-
dividual cells revealed that Cdc25A and -B exert speciﬁc
functions in the initiation of mitosis: Cdc25A may play a
role in chromatin condensation, whereas Cdc25B speciﬁ-
cally activates cyclin B1–Cdk1 on centrosomes.
 
Introduction
 
The master regulator of mitosis in mammalian cells is the pro-
tein complex consisting of cyclin B1 and Cdk1 (Cdc2). Cyclin
B1–Cdk1 accumulates in the cytoplasm and on centrosomes in
G2 phase and is believed to initiate centrosome separation and
mitotic spindle formation. Jackman et al. (2003) made the im-
portant observation that the centrosome is the site for the initial
activation of cyclin B1–Cdk1. Later in prophase, cyclin B1–Cdk1
translocates to the nucleus (Pines and Hunter, 1991), where a
larger pool of activated complexes is detected (De Souza et al.,
2000; Jackman et al., 2003).
Cyclin A also plays a role in mitosis. Cyclin A antibody
microinjections or small interfering RNA (siRNA) against
cyclin A delay cells in G2 phase, whereas injection of active
cyclin A–Cdk2 shortens G2 phase, but the exact action of cy-
clin A in mitotic entry is not clear (Pagano et al., 1992; Fu-
runo et al., 1999; Mitra and Enders, 2004). Cyclin A–Cdk2
has been suggested not only to promote progression into
prophase independently of cyclin B1–Cdk1 (Furuno et al.,
1999) but also to increase cyclin B1–Cdk1 activity by activat-
ing Cdc25B (Mitra and Enders, 2004) or by stabilizing cyclin B
(Lukas et al., 1999).
As the cyclin B1–Cdk1 complex accumulates in the S and
G2 phases of the cell cycle, Myt1 and Wee1 kinases keep Cdk1
inactive by phosphorylating two residues, Thr-14 and Tyr-15, in
Cdk1. A key event in the activation of cyclin B1–Cdk1 is the
removal of these two inhibitory phosphates. In 
 
Schizosaccha-
romyces pombe
 
 the dual-specificity phosphatase Cdc25 is re-
sponsible for the removal of the inhibitory phosphate on Tyr-15,
thus promoting cell cycle progression. In mammalian cells,
there are three Cdc25 isoforms—Cdc25A, -B, and -C—all of
which have been implicated in the regulation of mitosis (Obaya
and Sedivy, 2002; Donzelli and Draetta, 2003). A fundamental
question, therefore, is which of the Cdc25 isoforms is responsi-
ble for the activation of cyclin B1–Cdk1 at the centrosome.
The mammalian Cdc25s share a conserved COOH-termi-
nal catalytic domain (identity 60%), whereas the NH
 
2
 
-terminal
parts of the proteins are less similar (identity 20–25%). The non-
catalytic part of the phosphatase mediates regulation of activity
and intracellular trafficking through the presence of phosphory-
lation motifs, 14-3-3 binding sites, and nuclear export and import
signals. This region is also subject to alternative splicing, leading
to different splice versions of all Cdc25 isoforms. For Cdc25A
and -B, an additional level of regulation exists through their
rapid degradation, keeping interphase protein levels low.
Cdc25A is present from late G1 phase and throughout mitosis
and Cdc25B appears during S phase and disappears in mitosis,
whereas Cdc25C is present throughout the cell cycle (Donzelli
and Draetta, 2003; Kristjansdottir and Rudolph, 2004).
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Cdc25C was the first mammalian Cdc25 isoform to be
studied (Sadhu et al., 1990; Millar et al., 1991; Girard et
al., 1992). Microinjection of Cdc25C antibodies or overex-
pression of dominant-negative Cdc25C cause a block at
G2/M, suggesting a role for Cdc25C in the initiation of mi-
tosis (Millar et al., 1991; Lammer et al., 1998). Mammalian
Cdc25C is inactive during most of the cell cycle but is acti-
vated in mitosis by hyperphosphorylation mediated by cyclin
B1–Cdk1, suggesting a positive feedback loop (Hoffmann et
al., 1993; Strausfeld et al., 1994).
Cdc25B activity peaks before Cdc25C activity in mitosis,
which has led to the suggestion that the autoamplification loop
is initiated by Cdc25B (Lammer et al., 1998). As shown for
Cdc25C, Cdc25B antibodies or a dominant-negative version of
Cdc25B can block cells in G2 (Gabrielli et al., 1996; Lammer
et al., 1998). Cdc25B’s role in the initiation of mitosis is also
suggested by the findings that Cdc25B is more efficient than
Cdc25C in inducing premature mitosis in HeLa cells when
overexpressed (Karlsson et al., 1999) and that this phenotype is
associated with abnormal minispindles (Gabrielli et al., 1996;
Karlsson et al., 1999).
Cdc25A was originally thought to be active only at the
G1/S transition (Hoffmann et al., 1994; Jinno et al., 1994) but
has recently been implicated as a mitotic regulator as well.
Cdc25A levels increase through G2 and mitosis (Bernardi et
al., 2000; Donzelli et al., 2002; Mailand et al., 2002), and
Cdc25A overexpression induces mitotic events (Molinari et al.,
2000). Further, the Cdc25A protein is stabilized by phosphory-
lation in mitosis that is mediated by cyclin B1–Cdk1, and it
contributes to the activation of cyclin B1–Cdk1 (Donzelli et al.,
2002; Mailand et al., 2002). Down-regulation of Cdc25A by
siRNA was found to cause delays at both G1/S and G2/M tran-
sitions (Mailand et al., 2002).
The subcellular localizations of Cdc25 isoforms can
provide some information on which cyclin–Cdk complex they
activate. We and others have shown that both Cdc25A and -B
are mainly nuclear, although a fraction of Cdc25B accumulates
in the cytoplasm in G2 phase (Hoffmann et al., 1994; Gabrielli
et al., 1997b; Lindqvist et al., 2004; Källström et al., 2005).
Nuclear export of Cdc25B is needed for it to efficiently induce
premature mitosis, suggesting an important role of the cyto-
plasmic pool of Cdc25B (Lindqvist et al., 2004). A recent study
Figure 1. Cells with reduced Cdc25A or -B levels are delayed in
G2/M progression. (A) Specific siRNA targeting of Cdc25 isoforms.
HeLa cells were transfected with siRNA to Cdc25A (A), -B (B), -C (C),
-A and -B (AB), or Lamin A/C (Lam) in the first release of a double
thymidine block. 9 h after the second release (40 h after transfec-
tion), cells were harvested for Western blot. The antibodies used for
immunoblotting are indicated to the left of and transfected siRNAs
below the figure. The levels of Lamin B (arrow) indicate equal protein
loading (not affected by Lamin A/C silencing). NT, not transfected.
(B) FACS profiles of unsynchronized cells 24, 48, and 72 h after
transfection of siRNA to Cdc25A (A), -B (B), -C (C), -A and -B (AB),
or Lamin A/C (Lam). The x axis is logarithmic. (C) Outline of experi-
mental setup used when transfecting siRNA for collection of synchro-
nized cells at different time points. Cells were subjected to either a
single or a double thymidine block. (D) FACS profiles of synchro-
nized cells. HeLa cells were transfected with siRNA to Cdc25A (A),
-B (B), -C (C), or Lamin A/C (Lam). Samples were taken for FACS
analysis at 0, 6, and 12 h after release from a thymidine block. The
x axis is linear. (E) Time-lapse microscopy of synchronized cells.
SiRNA-injected HeLa or HEK293 cells were followed with time-lapse
microscopy after release from a thymidine block. The timing of mito-
sis of microinjected cells was compared with the timing of mitosis of
uninjected cells in the same dish. The siRNA used for injection and
the number of monitored cells is indicated in the graphs. Two differ-
ent sets of siRNA oligos were used (A, B, and C; A2, B2, and C2).
For an example of images from time-lapse microscopy, see Fig. 3 B. 
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reports the activation of Cdc25B by Aurora A kinase and a cen-
trosomal localization of activated Cdc25B (Dutertre et al.,
2004). Cdc25C was initially reported to be nuclear (Millar et
al., 1991; Girard et al., 1992), but later studies suggest that
Cdc25C is cytoplasmic in interphase and enters the nucleus
concomitantly with cyclin B1 in late prophase (Heald et al.,
1993; Dalal et al., 1999). However, all three Cdc25 phos-
phatases could have access to both nuclear cyclin A–Cdk2 as
well as centrosomal cyclin B1–Cdk1 because they all shuttle
across the nuclear membrane (Karlsson et al., 1999; Graves et
al., 2001; Källström et al., 2005).
In this paper we address the question of which Cdc25 is
needed for the initiation of mitosis in human cells by systemati-
cally targeting Cdc25s alone or in combination using RNA inter-
ference (RNAi). We demonstrate that targeting Cdc25A or -B
leads to a delay in G2 phase. Cells lacking both Cdc25A and -B
are unable to enter mitosis, suggesting that Cdc25C alone cannot
catalyze entry into mitosis. Based on analyses of single cells,
conducted by both time-lapse microscopy and quantification of
immunofluorescence, we conclude that Cdc25A and -B both me-
diate entry into mitosis but play partly different roles in this pro-
cess. In particular, we found that Cdc25B is specifically needed
for the activation of cyclin B1–Cdk1 at the centrosomes.
 
Results
 
siRNA-mediated targeting of Cdc25A or 
-B delays entry into mitosis
 
All three human Cdc25 phosphatases are suggested to play a
role in mitosis. To evaluate the role of the individual Cdc25
isoforms in mitotic entry, we used RNAi to reduce the levels of
Cdc25A, -B, and -C in HeLa and HEK293 cells. The siRNA
oligo sequences were designed to target all splice versions of
each Cdc25 homologue. Western blots on whole cell lysates of
G2 HeLa cells, 40 h after transfection with siRNA, showed that
the protein level of each Cdc25 could be specifically and effi-
ciently reduced by the siRNA treatment (Fig. 1 A).
To monitor the effect of Cdc25 siRNA targeting on the
cell cycle, we analyzed the DNA content of unsynchronized,
siRNA-transfected HeLa cells by FACS at 24, 48, and 72 h af-
ter transfection. After 24 h, the DNA profiles looked similar,
but after 48 and 72 h, an increased fraction of cells treated with
siRNA to Cdc25A or -B showed a 4N content, corresponding
to an accumulation in G2 or M phase (Fig. 1 B). Lamin A/C
siRNA was used as a control because Lamin A/C silencing
does not influence cell cycle progression (Harborth et al.,
2001). We did not observe any difference between cells trans-
fected with siRNA to Lamin A/C and Cdc25C. We also analyzed
cells that were synchronized in early S phase using thymidine
after the siRNA transfection and then harvested for FACS after
release from the thymidine block (Fig. 1 C). We found that
cells transfected with siRNA to either Cdc25A or -B again ac-
cumulated with a 4N DNA content (Fig. 1 D). Synchronized
cells transfected with siRNA to Cdc25C behaved as cells trans-
fected with the control Lamin A/C siRNA (Fig. 1 D) or
untransfected cells (not depicted). No delay in progression
through S phase was observed with any siRNA.
To monitor the timing of mitosis, time-lapse experiments
were performed. HeLa and HEK293 cells were microinjected
with siRNA, synchronized by a thymidine block, and followed
by time-lapse differential interference contrast microscopy. As
shown in Fig. 1 E, in both HeLa and HEK293 cells, the accu-
mulation of cells in mitosis was delayed after microinjection of
siRNA to Cdc25A or -B, whereas cells microinjected with
siRNA to Cdc25C behaved as uninjected cells. In this experi-
ment, two different sets of oligos were used to rule out unspe-
cific off-target effects. As demonstrated in Fig. 1 E, the results
from the second set (A2, B2, and C2) were very similar to the
results from the first set (A, B, and C). Thus, the time-lapse ex-
periments confirm that RNAi-mediated reduction of Cdc25A
or -B levels leads to a delay in the G2/M transition.
 
Cdc25A and -B cooperate to induce 
mitosis
 
SiRNA targeting of Cdc25A or -B caused a delay, but not a
block of the cell cycle, which may indicate some redundancy
between the isoforms. Therefore, we were interested in know-
ing the effect of suppressing the expression of more than one
Cdc25 in the cell. In an experiment similar to the ones depicted
in Fig. 1, we targeted the three Cdc25 homologues in all possi-
ble combinations. Combining siRNA to Cdc25C with siRNA
to either Cdc25A or -B did not further increase the time of the
delay seen when targeting Cdc25A or -B separately (unpublished
data). Simultaneous targeting of Cdc25A and -B, however,
caused a more prominent G2/M accumulation than targeting
Cdc25A and -B individually (unsynchronized cells, Fig. 1 B;
synchronized cells, Fig. 2). In fact, very few of the cells
cotransfected with siRNA to Cdc25A and -B were able to go
through mitosis and enter the next cell cycle during the time
course of the experiment (Fig. 2). This suggests that Cdc25A
and -B cooperate, and at least partly can compensate for each
other, in catalyzing entry into mitosis.
 
Cdc25A and -B are needed before 
prophase
 
To better define the cell cycle delay caused by Cdc25A or -B
siRNA, we harvested synchronized siRNA-transfected cells
Figure 2. Combining Cdc25A and -B siRNA leads to a cell cycle block.
HeLa cells were transfected with siRNA to Cdc25A (A), -B (B), -C (C), -A
and -B (AB), or Lamin A/C (Lam). Samples were harvested for FACS anal-
ysis at the indicated time points after release from a thymidine block. The
left graph shows the combined fractions of cells in G1 and S phases, and
the right graph shows cells in G2 or M phases. 
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for Western blot analysis with an experimental setup as de-
picted in Fig. 1 C. We chose to monitor cyclin A levels be-
cause cyclin A is degraded in prometaphase (den Elzen and
Pines, 2001; Geley et al., 2001). In untransfected cells or in
cells transfected with siRNA-targeting Cdc25C, a reduction
of cyclin A levels was observed after 
 
 
 
11 h (Fig. 3 A). In
cells transfected with siRNA to either Cdc25A or -B, cy-
clin A levels remained high after 12 h, indicating that these
cells had not entered prometaphase. In cells transfected with
siRNA targeting both Cdc25A and -B, cyclin A levels did not
decrease, demonstrating an accumulation of cells arrested
before prometaphase. Cyclin B1 degradation starts in meta-
phase, and a pattern similar to the one described for cyclin A
was observed when using cyclin B1 antibodies (unpublished
data).
These results are in agreement with observations from the
time-lapse experiments on living siRNA-treated cells described
in Fig. 1 E. As shown for cells treated with siRNA to Cdc25B,
these delayed cells have not entered prophase because the cells
remain flat and the DNA is not condensed (Fig. 3 B). Together,
these experiments demonstrate that the activities of Cdc25A
and -B are required before prophase.
 
Cyclin accumulation is regulated by 
Cdc25A and -B
 
It was previously reported that suppression of Cdc25A pro-
tein expression leads to a reduction of cyclin A levels (Tur-
owski et al., 2003), which caused us to more carefully moni-
tor by immunofluorescence the accumulation of cyclin A
and B1 in siRNA-treated cells. We microinjected cells with
Figure 3. The delay caused by siRNA to
Cdc25A or -B occurs before prophase. (A)
Transfection of siRNA to Cdc25A or -B leads
to a delay in cyclin A degradation. HeLa cells
were transfected and synchronized, and at the
indicated time points, samples were taken for
immunoblotting using cyclin A antibodies. The
time after release from a double thymidine
block is indicated below and siRNAs to the
left of the figure. NT, not transfected. (B) Cells
microinjected with siRNA to Cdc25A or -B are
delayed in G2 with uncondensed DNA. Time-
lapse images were acquired as in Fig. 1 E of
synchronized, siRNA-injected HeLa cells. Cells
on a single glass-bottomed dish were micro-
injected with or without Cdc25B siRNA to-
gether with a pYFP-histone H2B plasmid. The
first and last images show YFP-histone H2B
fluorescence at the start and at the end of the
experiment. The middle images were ac-
quired with differential interference contrast.
Bar, 10  m.
Figure 4. Cyclin accumulation is delayed in cells
injected with siRNA to Cdc25A or -B. HeLa cells were
microinjected with pCFP-Golgi as a marker for in-
jected cells, together with siRNA to Cdc25A, -B, or -C,
and fixed 8 h after release from a thymidine block.
Cells were stained with antibodies to cyclin A, cyclin
B1, and Cdc25B and the fluorescence was quantified
as described in Materials and methods. (A) Example
of images (maximum intensity projections) of cells in-
jected with siRNA to Cdc25B. Microinjected cells
(which express CFP-Golgi) are indicated by arrows.
Bar, 10  m. (B) Average fluorescence levels of
Cdc25B (left), cyclin A (middle), and cyclin B1 (right)
in siRNA-treated cells. The horizontal lines show the
average, whereas the vertical lines visualize the quar-
tiles of the quantified fluorescence. (C) Cyclin A and
B1 fluorescence in single cells. Nuclear cyclin A levels
(x axis) plotted against cytoplasmic cyclin B1 levels
(y axis) for individual cells. In each graph the injected
siRNA and number of quantified cells are shown. To
facilitate the comparison, the area that includes all un-
injected cells is marked in red and transferred to all
graphs. As shown, a subset of cells injected with
siRNA to Cdc25B express very little cyclin B1 but con-
tain high cyclin A levels. NI, not injected. 
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siRNA together with a plasmid to mark microinjected cells.
The cells were then synchronized, fixed, and stained with an-
tibodies to cyclin A and B1, as well as with Cdc25B antibod-
ies, to monitor the efficiency of the RNAi treatment. The pro-
tocol for acquiring comparable images for quantification is
described in Materials and methods. The fluorescence of be-
tween 46 and 77 cells was measured for each siRNA that was
microinjected. Fig. 4 B shows the average fluorescence of
Cdc25B, cyclin A, and cyclin B1 in siRNA-treated cells. We
noticed that cyclin B1 levels were reduced in cells treated
with either Cdc25A or -B siRNA, but not in cells treated with
siRNA to Cdc25C or CD46 (control) or in untreated cells
(Fig. 4 B). Also, average cyclin A levels were slightly lower
in cells treated with Cdc25A siRNA. As expected, Cdc25B
levels were greatly reduced in cells microinjected with siRNA
to Cdc25B.
To compare cyclin A and B1 levels in individual cells, we
plotted the cyclin A signal against the cyclin B1 signal for each
cell. A clear correlation between cyclin A and B1 levels was
observed (Fig. 4 C). At a certain cellular cyclin A level, cyclin
B1 staining starts to appear. After this threshold, the cyclin A
and B1 levels display an approximate linear correlation. Nota-
bly, however, in cells injected with Cdc25B siRNA, a subpopu-
lation of cells displayed high cyclin A levels with very low cy-
clin B1 levels. The high cyclin A levels in these cells suggest
that the lack of cyclin B1 accumulation is not a secondary ef-
fect of a G2 delay/arrest. Instead, it points to Cdc25B activity
being specifically needed for cyclin B1 accumulation. Microin-
jecting siRNA to Cdc25A or -C did not affect the correlation
between cyclin A and B1 levels (Fig. 4 C). The subcellular lo-
calization of cyclin A or B1 was not affected by microinjection
of any siRNA (unpublished data). In summary, this experiment
suggests that Cdc25A and -B activities are needed for the accu-
mulation of cyclin B1 and that Cdc25A is also required for the
accumulation of cyclin A.
 
siRNA to Cdc25A and -B have different 
effects on chromosome condensation 
and centrosome separation
 
The activation of cyclin B1–Cdk1 is initiated at the cen-
trosomes, when centrosome separation starts (Jackman et al.,
2003). In HeLa cells, the first visible sign of chromosome con-
densation occurs when the centrosomes have separated. Imme-
diately after chromosome condensation becomes visible, cyclin
B1–Cdk1 translocates to the nucleus, where it induces break-
down of nuclear lamins and enhances chromosome condensa-
tion. Because we showed in Figs. 1 and 3 that Cdc25A and -B
both have a role in the beginning of mitosis, we wished to in-
vestigate their involvement in early events, such as centrosome
separation and chromosome condensation.
Figure 5. Decreased time between centrosome sep-
aration and DNA condensation in a fraction of cells
injected with siRNA to Cdc25B. HeLa cells were micro-
injected with the marker plasmids pYFP-histone H2B
and pdsRED- -tubulin alone or together with siRNA to
Cdc25A or -B. After release from a thymidine block,
injected cells were followed by 3D time-lapse micros-
copy. (A) Examples of the behavior of cells entering
mitosis. Images show maximum intensity projections
of YFP-histone H2B and dsRED- -tubulin fluorescence.
The time between images is 12 min. (top) Normal mi-
totic progression of a cell injected with pYFP-histone
H2B and pdsRED- -tubulin. (middle) Delay between
centrosome separation and chromosome condensa-
tion in cell microinjected with siRNA to Cdc25A.
(bottom) Less than 12 min between centrosome sepa-
ration and chromosome condensation in cell injected
with siRNA to Cdc25B. Bar, 10  m. (B) Time be-
tween centrosome separation and DNA condensation
in a larger number of siRNA-treated cells. The number
of images between centrosome separation and DNA
condensation is shown below. The distance between
images is 12 min. (C) Centrosomes separate but re-
unite in a subset of cells injected with siRNA to
Cdc25B. Example of two cells microinjected with
siRNA to Cdc25B that do not enter mitosis in the time
frame of the experiment. The time after release from a
thymidine block is indicated below the figure. (D)
Quantification of centrosome distances before entry
into mitosis. Each graph presents the behavior of
three single cells. The distance between centrosomes
was measured in 3D and plotted against time. Time 0
is defined as first time point when DNA condensation
is clearly visible. 
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We microinjected siRNA together with plasmids coding
for YFP-histone H2B and 
 
Discosoma
 
 red fluorescent protein
(dsRED)-
 
 
 
-tubulin in synchronized HeLa cells to be able to
follow DNA condensation and centrosome separation with
three-dimensional (3D) time-lapse microscopy. Images were
collected every 12 min. In almost all cells microinjected with
only the marker plasmids, the centrosomes separated at be-
tween one and four time points (corresponding to 0–60 min)
before chromatin condensation was visible. The majority of
cells microinjected with siRNA to Cdc25A or -B behaved in a
manner similar to that of control cells. However, in a subset of
cells microinjected with siRNA to Cdc25A, the time between
centrosome separation and DNA condensation was prolonged.
In these cells, chromosomes had not condensed 1 h or more af-
ter the start of centrosome separation (Fig. 5, A and B).
The opposite was found for cells microinjected with
siRNA to Cdc25B. Here, a fraction of cells separated their
centrosomes very late in relation to chromatin condensation.
As exemplified in Fig. 5 (A and B), in these cells centrosome
separation and chromatin condensation became visible in the
same image. This was never observed in cells microinjected
with only the plasmids (Fig. 5, A and B) or a control siRNA
(not depicted).
Some cells injected with siRNA to Cdc25A or -B did not
enter mitosis in the time frame of the experiment (20 h after re-
lease from thymidine block). In this case, all cells microin-
jected with siRNA to Cdc25A were delayed before centrosome
separation had started. In contrast, some of the cells microin-
jected with siRNA to Cdc25B separated the centrosomes and
then reunited them (Fig. 5 C). This behavior could also be ob-
served in cells that divided during the experiment. To exclude
the possibility that centrosomes on opposite sides of the nu-
cleus were perceived as unseparated, we measured the distance
between centrosomes in 3D (Fig. 5 D). The centrosome separa-
tion seen here is clearly distinguished from normal centrosome
movement both in duration of the separation and in distance
between the centrosomes (Fig. 5, C and D).
These experiments suggest that Cdc25A and -B play dif-
ferent roles in mitotic entry. Cdc25A may take a larger part
in regulating chromosome condensation, whereas Cdc25B is
needed for centrosome separation.
 
Cyclin A–Cdk2 and cyclin B1–Cdk1 
activities are lower in cells treated with 
siRNA to Cdc25A and -B
 
Next, we sought to investigate the molecular mechanism be-
hind the G2 delay caused by siRNA to Cdc25A and -B in our
experiments. Cyclin B1–Cdk1 and cyclin A–Cdk2 are the main
cyclin–Cdk complexes active at the G2/M transition (Pines
and Hunter, 1989, 1990), and both can be dephosphorylated
by Cdc25A and -B in vitro, whereas Cdc25C can only effi-
ciently dephosphorylate cyclin B1–Cdk1 (Rudolph et al., 2001;
Mailand et al., 2002). We analyzed the phosphorylation shift
of Cdk1 by Western blot of synchronized siRNA-transfected
cells. A slower migrating form of Cdk1, corresponding to the
inactive kinase, appeared at the same time as cyclin B1, and
followed the increase in cyclin B1 levels in intensity. Approxi-
mately 11 h after release from a thymidine block, the slower
migrating form of Cdk1 disappeared in untransfected cells
and in cells transfected with siRNA to Cdc25C, demonstrat-
ing Cdk1 activation. In contrast, inactive Cdk1 persisted in
Cdc25A or -B siRNA-transfected cells (Fig. 6 A), suggesting
that both Cdc25A and -B take part in the activation of Cdk1 at
the G2/M transition. This is in agreement with previous studies
(Gabrielli et al., 1997a; Lammer et al., 1998; Donzelli et al.,
2002; Mailand et al., 2002).
We also investigated the effect of Cdc25 protein reduction
on cyclin A–Cdk2 complexes. Because we were unable to repro-
ducibly detect a phosphorylation shift of Cdk2, we performed hi-
stone H1 kinase assays. We synchronized siRNA-transfected
HeLa cells in late G2 and immunoprecipitated cyclin–Cdk com-
plexes with cyclin A antibodies. The activity of the complexes
was assessed by their ability to phosphorylate recombinant his-
tone H1 and was correlated to the amount of immunoprecipitated
Cdk2. The activity of cyclin A–Cdk2 was decreased in cells
transfected with Cdc25A and -B siRNA as compared with cells
transfected with Cdc25C and Lamin A/C siRNA (Fig. 6 B).
Thus, cyclin A–Cdk2 seems to be activated by both Cdc25A and
-B at G2/M as previously suggested (Lammer et al., 1998). It
should be noted, however, that rather small differences in Cdk2
activity are observed after Cdc25A and -B siRNA treatment.
This could be attributable to inhibitory phosphorylation being
less crucial for the regulation of Cdk2 than for that of Cdk1, as
suggested previously (Chow et al., 2003).
Figure 6. Reduced activities of both cyclin A–Cdk2 and cyclin B1–Cdk1 in
lysates of cells transfected with siRNA to Cdc25A or -B. (A) Delayed de-
phosphorylation of Cdk1 in cells treated with siRNA to Cdc25A or -B.
SiRNA-transfected synchronized cells were subjected to Cdk1 immunoblot-
ting. Arrows indicate the faster migrating unphosphorylated Cdk1 (bottom
band) and the slower migrating phosphorylated Cdk1 (top band). siRNAs
are indicated to the left. A quantification of the ratios of inactive versus ac-
tive Cdk1 is available in Fig. S1 (available at http://www.jcb.org/cgi/
content/full/jcb.200503066/DC1). (B) Reduced activation of cyclin
A–Cdk2 in cells treated with siRNA to Cdc25A or -B. Cyclin A was immu-
noprecipitated from siRNA-transfected cells 9 h after release from thymi-
dine block. The ability of the immunoprecipitate to phosphorylate histone
H1 as well as the amount of Cdk2 in the immunoprecipitate was assessed.
Bars show average from three independent experiments of normalized
ratio between cyclin A–Cdk2 activity and amount of Cdk2. 
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Cdc25B activates cyclin B1–Cdk1 on the 
centrosome
 
The two experiments depicted in Fig. 6 indicate that neither
cyclin B1–Cdk1 nor cyclin A–Cdk2 is efficiently activated in
the absence of Cdc25A or -B. However, these experiments
cannot provide information on Cdk activation in different sub-
cellular locations or relate the cyclin–Cdk activation to cyclin
levels in individual cells. Therefore, we developed a method by
which we could follow the Tyr-15 phosphorylation status of
Cdk1 in individual cells through the G2/M transition by immu-
nofluorescence. We microinjected different siRNAs together
with a marker plasmid on a single coverslip. After synchroniza-
tion, cells were fixed and stained with cyclin B1 and Y15P
Cdk1 (Cdk1-P) antibodies. The fluorescence signal was quanti-
fied in subcellular compartments of individual cells.
To evaluate the Cdk1-P antibody in immunofluorescence,
we first stained cells not treated with any siRNA. The Cdk1-P
staining appeared in the cytoplasm and on the centrosomes to-
gether with cyclin B1 staining in G2 cells but was close to
background levels in metaphase cells, showing that the anti-
body does not recognize unphosphorylated Cdk1 in immuno-
fluorescence (Fig. 7 A and Fig. S2 D, available at http://
www.jcb.org/cgi/content/full/jcb.200503066/DC1). We then
plotted the quantified Cdk-P fluorescence against the cyclin B1
fluorescence signal. In uninjected cells or in cells treated with a
control siRNA, the cytoplasmic Cdk1-P staining increased as
cyclin B1 levels increased (Fig. 7 B, left). This indicates that as
the cyclin B1–Cdk1 complex accumulates, Cdk1 is inactivated
by phosphorylation as expected. Thus, we believe that the
Cdk1-P antibody staining correctly represents the pool of inac-
tive cyclin B1–Cdk1 in the cell. When cells microinjected with
siRNA to Cdc25A or -B were observed 8 h after release from
the thymidine block, the accumulation of Cdk1-P was observed
to be similar to that in control cells both in the cytoplasm (Fig.
7 B) and on centrosomes (not depicted). However, the cyclin
B1 accumulation was delayed in these cells, confirming our
previous finding (Fig. 5 B). Thus, 8 h after release from a thy-
midine block, the siRNA-injected cells did not differ in Cdk1
Y15 phosphorylation but, rather, in the amount of cyclin B1–
Cdk1 complexes. Therefore, we turned our focus to a later time
point, when cyclin B1 had accumulated. 12 h after release from
a thymidine block, most of the cells injected with siRNA to
Cdc25C had entered mitosis, whereas a large portion of cells
injected with siRNA to Cdc25A or -B had still not divided (Fig.
7 A and not depicted). We quantified cytoplasmic as well as
centrosomal cyclin B1 and Cdk1-P immunofluorescence sig-
nals and measured the distance between the centrosomes in the
same cell. Centrosomes were considered separated when the
distance between them exceeded 2 
 
 
 
m.
When measuring the cytoplasmic fluorescence, we noticed
that cells with unseparated centrosomes injected with siRNA to
Cdc25B had slightly higher levels of both cyclin B1 and phos-
phorylated Cdk1, compared with cells injected with siRNA to
Cdc25A or -C (Fig. 7 C). This pattern was even more promi-
nent when we quantified the occurrence of cyclin B1 and phos-
phorylated Cdk1 on the centrosomes. In cells with separated
centrosomes, the centrosomal amount of Cdk1-P versus cyclin
B1 is slightly reduced compared with cells with unseparated
Figure 7. Cdc25B dephosphorylates cyclin B1–Cdk1 on
the centrosomes. HeLa cells were microinjected with
pCFP-Golgi together with siRNA to Cdc25A, -B, -C, or
CD46 after release of a double thymidine block and
fixed 8 or 12 h after release. Cells were stained with
antibodies to phosphorylated Cdk1 (Y15P Cdk1) and to
cyclin B1. The specificity of the Cdk1-P antibody is dem-
onstrated in Fig. S2 (available at http://www.jcb.org/
cgi/content/full/jcb.200503066/DC1). (A) Examples of
cells microinjected with siRNA to Cdc25B and stained
with Y15P Cdk1 12 h after release from thymidine block.
The Y15P Cdk1 staining is high on centrosomes in G2
cells but low in metaphase cells. Most surrounding cells
have passed through mitosis. Bar, 25  m. (B) Cytoplas-
mic cyclin B1 (x axis) and Y15P Cdk1 (y axis) fluores-
cence 8 h after release from a thymidine block. Each dot
corresponds to one cell. The diagonal line indicates the
levels of cyclin B1 and Y15P at which the control cells are
starting to activate Cdk1 (the Y15P Cdk1 accumulation
slows down). The fraction of cells above this line is indi-
cated in percent and in numbers of cells in each graph.
Cytoplasmic (C) and centrosomal (D) cyclin B1 (x axis)
and Y15P Cdk1 (y axis) fluorescence in G2 cells 12 h af-
ter release from a thymidine block. Red dots represent
cells with separated centrosomes and blue dots cells
where centrosomes are not separated. The diagonal line
indicates the levels of cyclin B1 and Y15P above which
the majority of control cells contain separated cen-
trosomes. The fraction of cells with unseparated cen-
trosomes above this line is indicated in percent and in
numbers of cells in each graph. Note that cells situated
above the diagonal line in B have not separated their
centrosomes and most probably correspond to cells below
the diagonal line in C. 
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centrosomes. This most likely reflects the activation of a pool
of cyclin B1–Cdk1 in these cells. In uninjected cells and in
cells injected with siRNA to Cdc25A or -C, most cells had sep-
arated their centrosomes before reaching a threshold level of
cyclin B1–Cdk1-P (Fig. 7 D). In cells injected with siRNA to
Cdc25B, however, 45% of the cells with unseparated cen-
trosomes had exceeded this threshold level (Fig. 7 D). Thus,
these cells accumulate with higher levels of inactive cyclin
B1–Cdk1 complex, suggesting that they are impaired in their
ability to dephosphorylate cyclin B1–Cdk1 on centrosomes.
Our results therefore strongly imply that Cdc25B activates
centrosomal cyclin B1–Cdk1.
 
Discussion
 
It has been known for almost 20 yr that Cdc25 phosphatases
regulate mitotic entry by activation of cyclin-dependent ki-
nases (Russell and Nurse, 1986, 1987). The original discovery
of Cdc25 in yeast led to the identification of three mammalian
Cdc25 isoforms: A, B, and C
 
.
 
 Subsequently, all three isoforms
were associated with the regulation of mitosis, but their indi-
vidual roles have remained obscure. In this paper, we have
used RNAi to show that Cdc25A and -B are required for entry
into mitosis in two different human cell lines. We also demon-
strate that Cdc25B is the Cdc25 isoform responsible for the ini-
tial activation of cyclin B1–Cdk1 on centrosomes.
We were somewhat surprised that we did not see a G2 de-
lay after siRNA-mediated targeting of Cdc25C. These results
are in contrast to recent ones reporting that interfering with
Cdc25C protein expression using antisense oligonucleotides or
RNAi caused a G2 delay (Bulavin et al., 2003; van Vugt et al.,
2004). The siRNA oligos used here efficiently reduce the levels
of Cdc25C expression (Fig. 1 A), and we can also monitor a
functional Cdc25C depletion in time-lapse experiments where
siRNA to Cdc25C causes a prometaphase delay in HeLa cells
(unpublished data). However, with regard to mitotic entry, cells
treated with siRNA to Cdc25C behave as control cells as ob-
served in two different human cell lines (HeLa and HEK293).
Moreover, transfection of siRNA to Cdc25C together with
Cdc25A or -B siRNA did not further increase the G2 delay
seen in the FACS analysis after targeting the A or B isoforms
alone. Thus, we conclude that Cdc25C is less crucial for entry
into mitosis than are Cdc25A and -B.
Experiments on knockout mice have shown that neither
Cdc25B nor -C is required for mouse development (Chen et al.,
2001; Lincoln et al., 2002). Moreover, the combined disruption
of Cdc25B and -C leads to normal mouse development and
normal somatic cell cycles in isolated cultures (Ferguson et al.,
2005). Thus, in mice, Cdc25A, or possibly other phosphatases,
can compensate for the loss of the B and C isoforms. It remains
to be understood whether there is a species difference in the re-
quirement for different Cdc25 isoforms, or if there is an adapta-
tion occurring in the developing animal as has been suggested
for other knockouts (Sage et al., 2003).
To analyze siRNA-mediated silencing in individual cells,
we have set up a novel experimental system, where microinjec-
tion of different siRNAs on a single coverslip, in combination
with immunostaining, allows us to quantify phosphorylation
status and amount of proteins in a comparative manner. We
were able to confirm that Cdk1 is phosphorylated and thus in-
active on the centrosomes as long as the centrosomes remain
unseparated and that centrosome separation correlates with a
portion of Cdk1 being dephosphorylated. These findings are
consistent with earlier observations (De Souza et al., 2000;
Jackman et al., 2003).
We further observe that cells treated with siRNA to
Cdc25B accumulate with high levels of inactive cyclin B1–
Cdk1 and unseparated centrosomes. This suggests that
Cdc25B is involved in activating cyclin B1–Cdk1 on cen-
trosomes. Other data presented here point to the same conclu-
sion: in 3D time-lapse microscopy experiments on living
cells, we were able to measure the distance between cen-
trosomes and correlate the process of centrosome separation
to that of chromatin condensation. In contrast to the behavior
of cells treated with siRNA to Cdc25A or -C, a subset of
Cdc25B siRNA-treated cells separated their centrosomes imme-
diately before DNA condensation, suggesting that centrosome
separation is delayed in these cells. In some cells microinjected
with siRNA to Cdc25B, centrosomes separated and then re-
united without any sign of chromosome condensation. Because
microinjection of siRNA (as well as transfection) gives a dis-
tribution of the efficiency of RNAi, it is possible that these
cells had enough Cdc25B activity to initiate centrosomal
Cdk1 activation and centrosome separation but not enough to
sustain the activity.
Circumstantial evidence previously suggested that Cdc25B
is the Cdc25 isoform responsible for centrosomal cyclin
B1–Cdk1 activation. Cdc25B overexpression was correlated
with prophase spindle formation (Gabrielli et al., 1996), and we
recently demonstrated that interfering with Cdc25B nuclear ex-
port leads to less efficient induction of mitosis (Lindqvist et al.,
2004). Furthermore, we observe a centrosomal localization of a
GFP-Cdc25B fusion protein (unpublished data), whereas Du-
tertre et al. (2004) observed a centrosomal localization of Cdc25B
using a phosphoantibody specific to Cdc25B phosphorylated at
Ser-353 by Aurora A kinase. Another recent study suggests
that the Chk1 kinase contributes to the timing of mitosis by
controlling the activity of centrosomal Cdc25B in an as yet un-
defined manner (Krämer et al., 2004).
In contrast to cells treated with Cdc25B siRNA, a subset
of cells microinjected with Cdc25A siRNA displayed a pro-
longed time between centrosome separation and chromatin
condensation. This suggests that Cdc25A is involved in the ini-
tiation of chromatin condensation in the nucleus, although it is
unclear which cyclin–Cdk is activated by Cdc25A. By immu-
nofluorescence we did not see any change in inactive Cdk1 lev-
els in the nuclei after treatment with siRNA to Cdc25A (un-
published data). It would be interesting to also analyze the
phosphorylation status of Cdk2 by immunofluorescence to de-
termine the effect of Cdc25A silencing on the cyclin A–Cdk2
complex.
It should be noted that a partial overlap of Cdc25A and -B
functions is likely. We have previously shown that, like cyclin
A and B1, both Cdc25A and -B shuttle between the nucleus 
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and the cytoplasm (Karlsson et al., 1999; Jackman et al., 2002;
Lindqvist et al., 2004; Källström et al., 2005). Moreover, many
Cdc25A or -B siRNA-injected cells, although delayed, entered
mitosis without an abnormal duration between centrosome sep-
aration and chromatin condensation.
When measuring cyclin levels in individual siRNA-
treated cells, we made the unexpected finding that cyclin B1
levels are lower in cells treated with siRNA to Cdc25A or -B.
Thus, the G2 delay caused by reduced Cdc25A or -B levels
could also be accounted for by a delay in cyclin B1 accumula-
tion. The accumulation of mitotic cyclins is mainly regulated by
transcription (Brandeis and Hunt, 1996; Eward et al., 2004).
Transcription factors known to stimulate the activity of the cy-
clin A and B promoters such as nuclear transcription factor Y
(NF-Y) and FoxM1 possess Cdk phosphorylation sites (Yun et
al., 2003; Major et al., 2004). In S and G2 phases, Cdk2 phos-
phorylates the NF-Y subunit YA, which mediates DNA binding
of NF-Y and enhances cyclin A and B transcription (Yun et al.,
2003; Chae et al., 2004). FoxM1 was shown to require phos-
phorylation of the Cdk site to recruit the cAMP-response ele-
ment-binding protein and to induce cyclin B1 transcription (Ma-
jor et al., 2004). Also, Cdc25B overexpression was found to
increase FoxM1-dependent transcription (Major et al., 2004). It
is therefore very likely that the observed delay in cyclin accu-
mulation observed here is the result of a reduction of transcrip-
tion-factor phosphorylation and, thus, reduced transcription.
When cells were transfected with siRNA to both Cdc25A
and -B, the G2 delay was longer than when siRNA was trans-
fected to each of these isoforms separately. We suggest that
Cdc25A and -B cooperate to induce mitosis by having specific
functional capacities. In late G2, Cdc25A activates a nuclear
cyclin–Cdk, leading to chromatin condensation, whereas
Cdc25B activates cyclin B1–Cdk1 on centrosomes.
 
Materials and methods
 
Cell culture and siRNA delivery
 
HeLa and HEK293 cells were grown in DME containing glutamax (GIBCO
BRL), supplemented with 10% FBS and antibiotics. Cells were synchronized
by a 24-h thymidine (2.5 mM) block or by two successive 24-h thymidine
blocks separated by 12 h. For transfection, cells were grown without anti-
biotics in 6-cm tissue culture plates. For all time series experiments, cells
transfected with a given siRNA were pooled and reseeded to reduce errors
caused by variation in transfection efficiency. Transfection was performed
with Oligofectamine or Lipofectamine 2000 (Invitrogen), resulting in a final
siRNA concentration of 10 pmol/cm
 
2
 
. Microinjection of siRNA was per-
formed as described previously (Lindqvist et al., 2004).
 
siRNA and antibodies
 
siRNA was purchased from Dharmacon Research, Inc. The oligos denoted
A, B, and C were designed to target a 19-mer fragment in the coding se-
quence of Cdc25A (CCTGACCGTCACTATGGAC), -B (Lindqvist et al.,
2004), and -C (CCTGCTCCTGGAGAGAGAC). The targeting sequences
for the Lamin A/C oligos and the second set of Cdc25 oligos (A2, B2,
and C2) have been published previously (Harborth et al., 2001; van Vugt
et al., 2004). CD46 siRNA was provided by A.-B. Jonsson (Uppsala Uni-
versity, Uppsala, Sweden). Mouse anti–cyclin B1 (GNS1), rabbit anti–
cyclin A (sc751), rabbit anti-Cdc25C (sc327), and mouse anti-Cdc25A
(sc7389) were obtained from Santa Cruz Biotechnology, Inc. Guinea pig
anti-Cdc25B (B1:5) is described in Lindqvist et al. (2004). Mouse anti-
Cdk1 (C12720) was purchased from Transduction Labs, mouse anti-Cdk2
(AN4.3) from Upstate Biotechnology, and rabbit anti–Y15-phosphorylated
Cdk1 (9112) from Cell Signaling Technology. For immunofluorescence,
Alexa488 goat anti–rabbit (Invitrogen), Cy3 donkey anti–mouse (Jackson
ImmunoResearch Laboratories), and Cy5 donkey anti–guinea pig (Jackson
ImmunoResearch Laboratories) were used as secondary antibodies before
mounting in vectashield mounting medium (Vector Laboratories).
 
FACS analysis
 
Cells were harvested with trypsin, washed twice in ice-cold PBS, and fixed
with 
 
 
 
20
 
 
 
C 70% ethanol. After incubation with 4 mg/ml of propidium Io-
dide and 10 mg/ml RNase A, cells were analyzed for DNA content by
flow cytometry on a FACSCalibur (Becton Dickinson).
 
Cyclin–Cdk activity assay
 
Cyclin A–Cdk2 complexes were immunoprecipitated from synchronized
siRNA-transfected cells, using anti–cyclin A antibodies and protein G–con-
jugated magnetic beads (Dynal). The immunoprecipitate was incubated
with histone H1 (Cdk1 kinase assay kit; Upstate Biotechnology) in the
presence of p33-labeled 
 
 
 
-ATP for 30 min at 30
 
 
 
C. The Cdk2 protein lev-
els were assessed by Western blot of the entire reaction mix, after which
the membrane was transferred to a phosphoimager (Fuji) for quantifica-
tion of p33 incorporation in histone H1.
 
Time-lapse microscopy
 
Cells growing on a glass-bottomed dish (MatTek) were microinjected
with 10 nM siRNA and 0.008 
 
 
 
g/
 
 
 
l YFP-histone H2B (provided by J.
Pines, Wellcome Trust/Cancer Research UK, Cambridge, UK) and, for
the experiment depicted in Fig. 5, with 0.0016 
 
 
 
g/
 
 
 
l dsRED-
 
 
 
-tubulin
(provided by J. Ellenberg, European Molecular Biology Laboratory,
Heidelberg, Germany). To reduce experimental variation, different siRNAs
were microinjected into different areas of cells growing in the same dish.
After a 24-h thymidine block, cells were moved to an imaging system
(Deltavision Spectris; Applied Precision) equipped with a heater and
CO
 
2
 
 chamber (Solent Scientific). For Figs. 1 and 3, images were ac-
quired on multiple locations every 15 min using a 20
 
 
 
 objective (NA
0.7; Olympus). For Fig. 5, 15 z levels with 1-
 
 
 
m spacing were acquired
on multiple locations in the dish every 12 min using a 60
 
 
 
 objective
(NA 1.4; Olympus). The distance between centrosomes was measured
using Softworx (Applied Precision). For figures, a maximum intensity pro-
jection was made of the z stack.
 
Quantification of fluorescence
 
Cells growing on a glass-bottomed dish (MatTek) or a coverslip were mi-
croinjected with 10 nM siRNA and 0.008 
 
 
 
g/
 
 
 
l plasmid CFP (pCFP)-
Golgi as a marker in the first release of a double thymidine block. As for
time-lapse microscopy, different siRNAs were introduced in different areas
of the same dish or coverslip. After release from the second thymidine
block, cells were fixed in 3% PFA and 2% sucrose in PBS and permeabi-
lized by adding 
 
 
 
20
 
 
 
C methanol. After antibody labeling, a 30-image z
stack with 0.5-
 
 
 
m spacing was acquired of injected cells using an imag-
ing system (Deltavision Spectris; Applied Precision) equipped with a 60
 
 
 
objective, NA 1.4 (Fig. 4), or a 15-image z stack with 1-
 
 
 
m spacing us-
ing a 20
 
 
 
 objective, NA 0.7 (Fig. 7). To avoid bleaching of antibody
fluorescence, cells were focused using the Hoechst labeling. Quantifications
were performed on nondeconvolved images. The images were corrected for
variation in illumination as determined by a photosensor (Applied Precision)
and corrected for flat-field and lightpath alignment invariance. For Fig. 4,
the average intensity of a rectangle with a 15-pixel side was measured in
the nucleus (cyclin A and Cdc25B) or in the cytoplasm (cyclin B1). For
Fig. 7, the peak intensity of the centrosomes and the average intensity
of a circle with a 10-pixel diam in the cytoplasm was measured using
Softworx. To exclude the possibility that bleaching affected quantification,
we quantified cells neighboring the injected cells and compared the inten-
sities from different areas.
 
Online supplemental material
 
Fig. S1 shows quantification of the Cdk1 phosphorylation shift in Fig. 6 A,
and Fig. S2 shows characterization of the Cdk1-Y15P antibody. Online
supplemental material is available at http://www.jcb.org/cgi/content/
full/jcb.200503066/DC1.
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